> Detailanzeige

Sveinbjornsson, Gardar; Ulfarsson, Magnus O.; Thorolfsdottir, Rosa B.; Jonsson, Benedikt A.; Einarsson, Eythor; Gunnlaugsson, Gylfi; Rognvaldsson, Solvi; Arnar, David O.; Baldvinsson, Magnus; Bjarnason, Ragnar G.; Eiriksdottir, Thjodbjorg; Erikstrup, Christian; Ferkingstad, Egil; Halldorsson, Gisli H.; Helgason, Hannes; Helgadottir, Anna; Hindhede, Lotte; Hjorleifsson, Grimur; Jones, David; Knowlton, Kirk U.; Lund, Sigrun H.; Melsted, Pall; Norland, Kristjan; Olafsson, Isleifur; [...]

Multiomics study of nonalcoholic fatty liver disease

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Multiomics study of nonalcoholic fatty liver disease
  • Beteiligte: Sveinbjornsson, Gardar; Ulfarsson, Magnus O.; Thorolfsdottir, Rosa B.; Jonsson, Benedikt A.; Einarsson, Eythor; Gunnlaugsson, Gylfi; Rognvaldsson, Solvi; Arnar, David O.; Baldvinsson, Magnus; Bjarnason, Ragnar G.; Eiriksdottir, Thjodbjorg; Erikstrup, Christian; Ferkingstad, Egil; Halldorsson, Gisli H.; Helgason, Hannes; Helgadottir, Anna; Hindhede, Lotte; Hjorleifsson, Grimur; Jones, David; Knowlton, Kirk U.; Lund, Sigrun H.; Melsted, Pall; Norland, Kristjan; Olafsson, Isleifur; [...]
  • Erschienen: Springer Science and Business Media LLC, 2022
  • Erschienen in: Nature Genetics, 54 (2022) 11, Seite 1652-1663
  • Sprache: Englisch
  • DOI: 10.1038/s41588-022-01199-5
  • ISSN: 1061-4036; 1546-1718
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractNonalcoholic fatty liver (NAFL) and its sequelae are growing health problems. We performed a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and integrated the findings with expression and proteomic data. For NAFL, we utilized 9,491 clinical cases and proton density fat fraction extracted from 36,116 liver magnetic resonance images. We identified 18 sequence variants associated with NAFL and 4 with cirrhosis, and found rare, protective, predicted loss-of-function variants inMTARC1andGPAM, underscoring them as potential drug targets. We leveraged messenger RNA expression, splicing and predicted coding effects to identify 16 putative causal genes, of which many are implicated in lipid metabolism. We analyzed levels of 4,907 plasma proteins in 35,559 Icelanders and 1,459 proteins in 47,151 UK Biobank participants, identifying multiple proteins involved in disease pathogenesis. We show that proteomics can discriminate between NAFL and cirrhosis. The present study provides insights into the development of noninvasive evaluation of NAFL and new therapeutic options.